摘要
目的观察哌拉西林/他唑巴坦(4∶1)治疗肝硬化合并自发性腹膜炎(SBP)的临床疗效和安全性。方法 20例患者给予哌拉西林/他唑巴坦(4∶1)2.5g静脉滴注,1次/12h,疗程5～8d;19例患者给予头孢噻肟钠2g静脉滴注,1次/8h,疗程7～14d;观察治疗前后患者的症状、体征、肝功能、不良反应等。结果哌拉西林/他唑巴坦(4∶1)组与头孢噻肟组的临床总有效率分别为95.00%与94.74%,两组差异无统计学意义;治愈率、显效率为60.00%、85.00%与42.10%、73.67%,两组差异有统计学意义(P<0.05);不良反应发生率为5.00%和5.26%。结论哌拉西林/他唑巴坦(4∶1)有效地控制自发性腹膜炎患者的细菌感染,安全性高,可以作为经验性治疗SBP的首选抗菌药物。
OBJECTIVE To observe the clinical efficacy and safety of piperacillin/tazobactam（4∶1） in the treatment of cirrhosis and spontaneous bacterial peritonitis（SBP）.METHODS A total of 20 patients were given 2.5 g of piperacillin/tazobactam（4∶1） intravenously for once per 12 hours with the course of treatment from 5 to 8 days,and 19 patients were given 2 g of cefotaxime sodium intravenously for once per 8 hours with the treatment course from 7 to 14 days.The symptoms,signs,liver function,and the adverse reactions of the patients were observed before and after the treatment.RESULTS The total clinical effective rates of the piperacillin/tazobactam（4∶1） group and the cefotaxime group were 95.00% and 94.74%,respectively,the difference was not statistically significant（P0.05）,the cure rate and the markedly effective rate were 60.00%,85.00% and 42.10%,73.67%,respectively,the differences were statistically significant（P0.05）,the incidence rates of the adverse reaction were 5.00% and 5.26%.CONCLUSION Piperacillin/tazobactam（4∶1） can effectively control the bacterial infections in patients with spontaneous bacterial peritonitis,which can be used as the preferred antimicrobial agents for empirical treatment of SBP.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2013年第3期657-659,共3页
Chinese Journal of Nosocomiology
关键词
哌拉西林
他唑巴坦
肝硬化
自发性腹膜炎
Piperacillin/tazobactam
Cirrhosis
Spontaneous bacterial peritonitis
